Precision radiation boost after chemo shows promise for tough lung cancers

NCT ID NCT00945451

Completed Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a precise, high-dose radiation treatment called CyberKnife after standard chemo and radiation could help people with stage III non-small cell lung cancer. It included 35 patients who had 1 to 3 small tumors left after initial treatment. The goal was to find the safest dose and see how well it shrank tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CyberKnife radiosurgery (a precise type of radiation)
What this could lead to: If it works, this could offer a way to boost tumor control for people with stage III lung cancer who cannot have surgery.
What could go wrong: This was a small, early-phase study (35 people) looking at side effects and best dose, not a large test of effectiveness. The added radiation may cause more lung or esophageal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.